← Back to patent-cliff list
CAS 32384-65-9
(3R,4S,5R,6R)-3,4,5-tris((trimethylsilyl)oxy)-6-(((trimethylsilyl)oxy)methyl)tetrahydro-2H-pyran-2-one
Codes: EMPA-007, DAPA-005, CANA-006, IPRA-012, ERTU-013, HENAG-007
Application context (from source-drug indications)
Chronic renal impairmentEmpagliflozinHeart failureEmpagliflozinType 2 diabetesEmpagliflozinType 2 diabetesDapagliflozin Propanediol/Metformin HydrochlorideEnd-stage renal diseaseCanagliflozin/Metformin HydrochlorideCardiac and vascular disordersCanagliflozin/Metformin HydrochlorideAbdominal aortic aneurysmCanagliflozin/Metformin HydrochlorideType 2 diabetesCanagliflozin/Metformin HydrochlorideType 2 diabetesSitagliptin Phosphate Monohydrate/Ipragliflozin L-ProlineType 2 diabetesErtugliflozinMitral regurgitationErtugliflozinLeft ventricular dysfunctionErtugliflozinHeart failureErtugliflozinAtherosclerosisErtugliflozinInsulin resistanceErtugliflozinChronic renal impairmentDapagliflozin Propanediol MonohydrateHeart failureDapagliflozin Propanediol MonohydrateKidney diseaseDapagliflozin Propanediol MonohydrateType 1 diabetesDapagliflozin Propanediol MonohydrateType 2 diabetesDapagliflozin Propanediol MonohydratePolycystic ovary syndromeDapagliflozin Propanediol MonohydrateType 2 diabetesCanagliflozin HemihydrateDiabetic nephropathyCanagliflozin HemihydrateCoronary artery lesionCanagliflozin HemihydrateDiabetesCanagliflozin HemihydrateHeart failureCanagliflozin HemihydrateEnd-stage renal diseaseCanagliflozin HemihydrateType 2 diabetesIpragliflozin L-ProlineType 1 diabetesIpragliflozin L-ProlineDiabetesIpragliflozin L-ProlineLiver diseaseIpragliflozin L-ProlineType 2 diabetesHenagliflozin ProlineDiastolic heart failureHenagliflozin ProlineNon-alcoholic steatohepatitisHenagliflozin ProlineKidney diseaseHenagliflozin ProlineDiabetesHenagliflozin ProlineHepatic function declineHenagliflozin Proline
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Empagliflozin | Tier A — Act now | 2028 |
| Dapagliflozin Propanediol/Metformin Hydrochloride | Tier A — Act now | 2030 |
| Canagliflozin/Metformin Hydrochloride | Tier B — Position early | 2029 |
| Sitagliptin Phosphate Monohydrate/Ipragliflozin L-Proline | Tier C — Watch / trade | - |
| Ertugliflozin | Tier C — Watch / trade | - |
| Dapagliflozin Propanediol Monohydrate | Tier B — Position early | - |
| Canagliflozin Hemihydrate | Tier C — Watch / trade | - |
| Ipragliflozin L-Proline | Tier C — Watch / trade | - |
| Henagliflozin Proline | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
5-bromo-2-chlorobenzoic acid→anisole→(5-bromo-2-chlorophenyl)(4-methoxyphenyl)methanone→4-bromo-1-chloro-2-(4-methoxybenzyl)benzene→4-(5-bromo-2-chlorobenzyl)phenol→(4-(5-bromo-2-chlorobenzyl)phenoxy)(tert-butyl)dimethylsilane→(3R,4S,5R,6R)-3,4,5-tris((trimethylsilyl)oxy)-6-(((trimethylsilyl)oxy)methyl)tetrahydro-2H-pyran-2-one→(2S,3R,4S,5S,6R)-2-(4-chloro-3-(4-hydroxybenzyl)phenyl)-6-(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol→(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-hydroxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol→(R)-tetrahydrofuran-3-yl 4-methylbenzenesulfonate→(3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-one
(3R,4S,5R,6R)-3,4,5-tris((trimethylsilyl)oxy)-6-(((trimethylsilyl)oxy)methyl)tetrahydro-2H-pyran-2-one→2-chloro-5-iodobenzoic acid→fluorobenzene→(2-chloro-5-iodophenyl)(4-fluorophenyl)methanone→(S)-tetrahydrofuran-3-ol→(S)-(2-chloro-5-iodophenyl)(4-((tetrahydrofuran-3-yl)oxy)phenyl)methanone→(S)-3-(4-(2-chloro-5-iodobenzyl)phenoxy)tetrahydrofuran→(2S,3R,4S,5R,6R)-2-(4-chloro-3-(4-(((S)-tetrahydrofuran-3-yl)oxy)benzyl)phenyl)-3,4,5-tris((trimethylsilyl)oxy)-6-(((trimethylsilyl)oxy)methyl)tetrahydro-2H-pyran-2-ol→(2S,3R,4S,5S,6R)-2-(4-chloro-3-(4-(((S)-tetrahydrofuran-3-yl)oxy)benzyl)phenyl)-6-(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol
(3R,4S,5R,6R)-3,4,5-tris((trimethylsilyl)oxy)-6-(((trimethylsilyl)oxy)methyl)tetrahydro-2H-pyran-2-one→(S)-3-(4-bromophenoxy)tetrahydrofuran→5-bromo-2-chlorobenzaldehyde→(5-bromo-2-chlorophenyl)(4-(((S)-tetrahydrofuran-3-yl)oxy)phenyl)methanol→((5-bromo-2-chlorophenyl)(4-(((S)-tetrahydrofuran-3-yl)oxy)phenyl)methoxy)trimethylsilane→(2S,3R,4S,5R,6R)-2-(4-chloro-3-((4-(((S)-tetrahydrofuran-3-yl)oxy)phenyl)((trimethylsilyl)oxy)methyl)phenyl)-3,4,5-tris((trimethylsilyl)oxy)-6-(((trimethylsilyl)oxy)methyl)tetrahydro-2H-pyran-2-ol→(2S,3R,4S,5S,6R)-2-(4-chloro-3-(methoxy(4-(((S)-tetrahydrofuran-3-yl)oxy)phenyl)methyl)phenyl)-6-(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol
(3R,4S,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol→(2R,3R,4R,5S,6S)-2-(acetoxymethyl)-6-(4-chloro-3-(4-ethoxybenzyl)phenyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate→5-bromo-2-chlorobenzoic acid→ethoxybenzene→(5-bromo-2-chlorophenyl)(4-ethoxyphenyl)methanone→4-bromo-1-chloro-2-(4-ethoxybenzyl)benzene→(3R,4S,5R,6R)-3,4,5-tris((trimethylsilyl)oxy)-6-(((trimethylsilyl)oxy)methyl)tetrahydro-2H-pyran-2-one
5-bromo-2-chlorobenzoic acid→ethoxybenzene→(5-bromo-2-chlorophenyl)(4-ethoxyphenyl)methanone→4-bromo-1-chloro-2-(4-ethoxybenzyl)benzene→(3R,4S,5R,6R)-3,4,5-tris((trimethylsilyl)oxy)-6-(((trimethylsilyl)oxy)methyl)tetrahydro-2H-pyran-2-one→(3R,4S,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol→L-proline compound with (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (2:1)
Intermediates available on this site
Side-by-side comparison of all listed offers on this CAS; price bands are list-price ranges, final price subject to RFQ confirmation.
| Supplier | Product | Price band | MOQ | Lead time | Qualifications | Action |
|---|---|---|---|---|---|---|
| Unibest Taizhou GMP-like Site | 2,3,4,6-Tetrakis-0-trimethylsilyl-D-gluconolactone Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Nantong cGMP Site | 2,3,4,6-Tetrakis-O-trimethylsilyl-D-gluconolactone Pharmaceutical Intermediates | On request | On request | On request | — |
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.